Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization

This publication has 23 references indexed in Scilit:

• Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade
  Circulation, 1998
• Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
  Journal of the American College of Cardiology, 1996
• Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
  The American Journal of Cardiology, 1995
• Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy
  Circulation, 1995
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
  Circulation, 1994
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty
  American Heart Journal, 1989
• Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary Angioplasty
  New England Journal of Medicine, 1988
• The platelet membrane glycoprotein IIb-IIIa complex
  Blood, 1988
• Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model.
  Circulation Research, 1985